Among the neuropeptide and neurotransmitter pathways implicated in anxiety development, the amygdala-synthesized thyrotropin-releasing hormone (TRH) is a promising candidate, given that its intraventricular (i.v.)administration reduces rats’ anxiety levels when subjected to the defensive burying behavioral test (DBT) and, also, since TRH mRNA expression in the amygdala is negatively correlated with rats’ anxiety levels analyzed during the same test [17]. The gene discussed is TRH; the disease is Anxiety.